dr. mato discusses a phase ii trial of umbralisib in cll
Published 6 years ago • 260 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
1:29
dr. mato discusses the safety and efficacy of umbralisib in cll
-
0:59
dr. mato on the use of biosimilars in cll
-
1:17
dr. mato on managing side effects with ibrutinib/idelalisib in cll
-
1:44
dr. mato on ibrutinib-based combinations in cll
-
1:50
dr. mato on ibrutinib versus acalabrutinib in cll
-
0:45
dr. mato discusses the benefits of the jtcc retrospective trial
-
2:55
umbralisib for cll patients intolerant to btk inhibitors
-
1:22
dr. davids on updated data with ibrutinib/umbralisib in r/r cll and mcl
-
1:39
umbralisib plus ublituximab vs. standard of care chemoimmunotherapy in cll
-
1:22
dr. davids on rationale for ibrutinib/umbralisib combo in r/r cll and mcl
-
1:07
dr. davids on the potential utility of ibrutinib/umbralisib in mcl and cll
-
1:29
dr. anthony mato on the difference between intolerance and resistance in cll
-
0:47
dr. davids on remaining questions with umbralisib/ibrutinib in cll and mcl
-
8:43
understanding chronic lymphocytic leukemia with anthony mato, md
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
2:01
ublituximab, umbralisib and ibrutinib in cll and nhl
-
50:25
the latest cll treatments and therapies with dr jan burger
-
0:47
dr. davids on the potential utility of frontline ibrutinib/umbralisib in mcl and cll
-
5:12
phase ii trial of acalabrutinib, lenalidomide and rituximab in patients with mcl